Related Experiment Videos
Double-antibody immunoenzyme assay for human prostatic acid phosphatase
Clinical Chemistry
|December 1, 1980
Summary
This study compares radioimmunoassay (RIA) and immunoenzyme assay (IEA) for measuring prostatic acid phosphatase. Both methods showed high correlation, but IEA yielded lower normal values, potentially reducing false positives in clinical diagnostics.
Area of Science:
- Biochemistry
- Clinical Chemistry
- Immunology
Background:
- Prostatic acid phosphatase (PAP) is a biomarker for prostate cancer.
- Accurate measurement of PAP is crucial for diagnosis and monitoring.
- Radioimmunoassay (RIA) and Immunoenzyme Assay (IEA) are common methods for PAP quantification.
Purpose of the Study:
- To compare the performance of double-antibody RIA and IEA for measuring serum PAP.
- To evaluate assay precision, accuracy, and normal reference ranges for both methods.
Main Methods:
- Double-antibody radioimmunoassay (RIA).
- Immunoenzyme assay (IEA).
- Analysis of serum samples from 385 normal individuals.
Main Results:
- IEA produced lower mean PAP values (1.02 µg/L) compared to RIA (2.69 µg/L).
- Results from both assays were highly correlated (r = 0.9813).
- Using a normal range defined as mean + 2 SD, IEA showed a lower false-positive rate (3-10%) than RIA.
Conclusions:
- IEA is a viable alternative to RIA for serum PAP measurement.
- IEA may offer improved specificity and a reduced false-positive rate in clinical settings.
- Further studies are warranted to establish definitive reference ranges for IEA.